FU FUL H.B. Fuller Company Загрузка... : Бычьи и медвежьи мнения аналитиков

H.B. Fuller should sell its lower-margin, lower-growth adhesives unit for $1.2 billion to inject cash and address its serious leverage issues following the dilutive AMS acquisition; failure to engage will result in a broader activist campaign.

Ancora's proposed purchase of H.B. Fuller's building adhesives unit would inject about $1 billion of cash and directly address the company's post-AMS leverage problem of over 4x leverage and more than $3 billion in net debt. It would also let management focus on integrating the higher-growth AMS acquisition and remove a lower-margin, lower-growth segment. If H.B. Fuller's board does not engage, Ancora is prepared to run a broader activist campaign and push strategic alternatives, which Chadwick frames as value-maximizing for shareholders.

The company is executing its strategic plan to move into high-margin medical adhesives via the AMS acquisition. Despite activist pushback, management believes this will drive the best value for shareholders and has already improved EBITDA margins by 400 basis points.

The acquisition of Advanced Medical Solutions provides a platform to expand the medical adhesives business into a fourth division, representing about 10% of revenue and growing at high single digits. Strong cash flow generation from the acquired assets will enable rapid deleveraging, potentially faster than the historical half-turn-per-year pace, increasing shareholder value.

Premarket movers report shows semiconductor stocks surging while hyperscalers decline, along with significant moves in ARS Pharmaceuticals, Bio-Techne, BlackBerry, Dollar Tree, HB Fuller, IBM, Jefferies Financial, Micron Technology, Trip.com ADRs, Qualcomm, and Wendy's.

Alphabet, Fulcrum, HP Enterprise, and Marvell are among the stocks highlighted as gaining Wall Street's attention before the market opens.

H.B. Fuller is undervalued, trading at a significant discount to its intrinsic value and to peers, with strong private equity interest. Management's proposed acquisition of AMS is value-destructive, levering up the balance sheet to buy at a high multiple. The company should pursue a strategic review or outright sale to maximize shareholder value.

H.B. Fuller reported mixed Q1 results with a decline in organic revenue offset by growth in adjusted EPS.